European regulatory perspectives for innovative therapies

Osteoporosis International

Volumn 19, Issue 6, 2008, Pages 725-731

  Ormarsdottir, S ^a   Reginster, J Y ^b,c,d,f   Abadie, E ^e  

^a Icelandic Medicines Control Agency   (Iceland)

^b European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

^c Group for the Respect of Ethics and Excellence in Science (GREES)

^d AFSSAPS ^*

^e UNIVERSITY OF LIÈGE   (Belgium)

^f Policliniques L BRULL Quai Godefroid Kurth   (Belgium)

Author keywords

Academia; Drug development; European Medicines Agency; Innovative medicines; Pharmaceutical industry; Regulatory requirements

Indexed keywords

BIOLOGICAL MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG APPROVAL; DRUG FORMULARY; DRUG INDUSTRY; DRUG RESEARCH; ENVIRONMENTAL CHANGE; EUROPE; EXPERIMENTAL THERAPY; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK BENEFIT ANALYSIS;

BONE DENSITY CONSERVATION AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; EUROPE; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG; OSTEOPOROSIS; TECHNOLOGY, PHARMACEUTICAL;

EID: 43249123913     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0576-4     Document Type: Review

References (26)

1. Directive 2001/20/EC of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (Official Journal L 121, 1/5/2001 p. 34-44). http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/
2. Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products (Official Journal L 91, 9/4/2005 p. 13-19). http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/
3. Commission Directive 2003/94/EC of 8 October 2003 laying down the principle and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use (Official Journal L 262, 14/10/2003 p. 22-26). http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/
4. Reginster JY (2007) The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56:2005-2010
5. Bresalier RS (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. NEJM 352:1092-1102
6. Regulation (EC) No 726/2004 of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Official Journal L 136, 30/4/2004 p. 1-24). http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/
7. Regulation (EC) No 141/2000 of 16 December 1999 on orphan medicinal products (Official Journal L 18, 22/1/2000 p. 1 - 5). http://ec.europa.eu/ enterprise/pharmaceuticals/eudralex/
8. Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts 'similar medicinal product' and' clinical superiority' (Official Journal L 103, 28/4/2000 p. 5 - 8). http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/
9. Regulation (EC) No 1901/2006 of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Official Journal L 378, 27/12/2006 p. 20-21). http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/
10. Regulation (EC) No 1905/2005, of 14 November 2005, amending Regulation (EC) No 297/95 on fees payable to the European Medicines Agency (Official Journal L 340, 13/11/2005 p. 1 - 9). http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/
11. Regulation (EC) No 2049/2005, of 15 December 2005, laying down, pursuant to Regulation (EC) No 726/2004 of the European Parliament and of the Council, rules regarding the payment of fees to, and the receipt of administrative assistance from, the European Medicines Agency by micro, small and medium-sized enterprises (Official Journal L 329, 16/12/2005 p. 4 - 7). http://ec.europa.eu/ enterprise/pharmaceuticals/eudralex/
12. Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council (Official Journal L 92, 30/3/2006 p. 6 - 9). http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/
13. Medicines and Emerging Science-Advanced Therapies http://www.emea.europa. eu/htms/human/mes/advancedtherapies.htm
14. Health and the EU Lisbon Agenda http://www.efpia.org/6_publ/ Healthlisbonagenda.pdf
15. Abadie E, Ethgen D, Avouac B, et al. (2004) Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthr Cartil 12:263-268
16. Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus CPMP/EWP/1080/00. http://www.emea.europa.eu/pdfs/ human/ewp/108000cn.pdf
17. Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis. CPMP/EWP/552/95. http://www.emea.europa.eu/pdfs/human/ewp/ 55295enfin.pdf
18. Reginster JY, Gieschke R (2006) Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Curr Drug Metab 7:827-836
19. Reflection Paper on Methodological issues in confirmatory clinical trials with flexible design and analysis plan. CHMP/EWP/2459/02 http://www.emea. europa.eu/pdfs/human/ewp/245902cn.pdf
20. Survey 2006 on the performance of EMEA scientific procedures for medicinal products for human use (EMEA/489472/2006). http://www.emea.europa.eu/ pdfs/general/direct/48948206en.pdf
21. Committee for Medicinal Products for Human Use (CHMP) CHMP Members http://www.emea.europa.eu/htms/general/contacts/CHMP/CHMP_members.html
22. Reginster JY, Abadie E, Delmas PD, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B (2006) Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 17:1-7
23. World Medical Association declaration of Helsinki (1997) Recommendation guiding physician and biochemical research involving human subjects. JAMA 277:225-226
24. Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY; Group for the Respect of Ethics and Excellence in Science (GREES) (2002) The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13:1-5
25. Silverman SL, Cummings SR, Watts NB; for the Consensus Panel of the ASBMR, ISCD, and NOF (2008) Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res 23:159-165
26. Confidentiality Arrangements concluded between the EU (EC and EMEA) and the US FDA/DHHS Implementation Plan for Medicinal Products for Human Use. http://www.emea.europa.eu/pdfs/general/direct/pr/confidentiality.pdf